Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.
Stocks · News reference
8-K filing — Viatris Inc (VTRS)
Filed: 2026-10-08 AccNo: 0001140361-26-039024 Size: 6 MB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Pacira BioSciences Skyrocketed Today
Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business.
Viatris Announces $1.65B Deal To Acquire Pacira BioSciences For $36.50/Share In Cash; Expects Close By End Of 2026